Prelude Therapeutics/$PRLD
1D1W1MYTD1Y5YMAX
Capital at risk
About Prelude Therapeutics
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
- Ticker
- $PRLD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 79
- Headquarters
- Wilmington, United States
- Website
- preludetx.com
PRLD Metrics
BasicAdvanced
$473M
-
-$0.72
0.94
-
Price and volume
Market cap
$473M
Beta
0.94
52-week high
$6.83
52-week low
$0.98
Average daily volume
496K
Financial strength
Current ratio
4.072
Quick ratio
3.989
Long term debt to equity
11.12
Total debt to equity
13.198
Profitability
EBITDA (TTM)
-64.51
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-269.75%
Operating margin (TTM)
-294.76%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-27.15%
Return on equity (TTM)
-57.73%
Valuation
Price to revenue (TTM)
17.237
Price to book
3.53
Price to tangible book (TTM)
3.53
Price to free cash flow (TTM)
-11.623
Free cash flow yield (TTM)
-8.60%
Free cash flow per share (TTM)
-0.395
Growth
Revenue change (TTM)
220.34%
Earnings per share change (TTM)
-56.13%
3-year earnings per share growth (CAGR)
-32.59%
What the Analysts think about PRLD
Analyst ratings (Buy, Hold, Sell) for Prelude Therapeutics stock.
Analyst projections of the future price of Prelude Therapeutics stock.
Bulls say / Bears say
As of June 30, 2026, Prelude held $155.2 million in cash, cash equivalents and marketable securities, extending its cash runway into the second quarter of 2028 to fund ongoing programs (SEC Filing & Press Release)
The FDA cleared an IND for PRT12396, Prelude’s mutant-selective JAK2V617F inhibitor, enabling initiation of a Phase 1 study in polycythemia vera and myelofibrosis by Q2 2026 (Press Release & Press Release)
Prelude remains on track to file an IND for its first-in-class oral KAT6A degrader PRT13722 by mid-2026, with a Phase 1 study initiation expected in the second half of 2026, expanding its pipeline into HR+/HER2- breast cancer (Press Release)
Prelude’s underwritten offering in April 2026 raised $90 million through the sale of over 18 million shares at $4.44 per share, diluting existing shareholders (Press Release)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
PRLD Financial Performance
Revenues and expenses
PRLD Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing PRLD
Fund name | Fund size | $PRLD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.